Segall Bryant & Hamill LLC increased its stake in shares of Danaher Corporation (NYSE:DHR) by 9.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 341,041 shares of the conglomerate’s stock after purchasing an additional 28,563 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Danaher were worth $29,254,000 as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of the stock. GQG Partners LLC acquired a new stake in Danaher in the second quarter valued at approximately $101,000. Proficio Capital Partners LLC lifted its stake in Danaher by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock valued at $105,000 after acquiring an additional 598 shares during the last quarter. Monetary Management Group Inc. lifted its stake in Danaher by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after acquiring an additional 150 shares during the last quarter. Acrospire Investment Management LLC raised its position in shares of Danaher by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after purchasing an additional 1,100 shares during the period. Finally, Motco raised its position in shares of Danaher by 8.8% in the second quarter. Motco now owns 2,011 shares of the conglomerate’s stock valued at $170,000 after purchasing an additional 163 shares during the period. Institutional investors and hedge funds own 76.32% of the company’s stock.
Shares of Danaher Corporation (NYSE DHR) opened at $93.18 on Friday. Danaher Corporation has a 52 week low of $77.45 and a 52 week high of $94.82. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The company has a market cap of $64,468.69, a price-to-earnings ratio of 23.83, a PEG ratio of 2.20 and a beta of 1.02.
Danaher (NYSE:DHR) last issued its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.87 EPS. sell-side analysts expect that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a dividend of $0.14 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.56 annualized dividend and a yield of 0.60%. Danaher’s dividend payout ratio (DPR) is 16.52%.
A number of equities analysts have recently commented on DHR shares. J P Morgan Chase & Co reissued an “overweight” rating and issued a $95.00 price target on shares of Danaher in a research report on Friday, September 8th. Goldman Sachs Group reissued a “neutral” rating and issued a $83.00 price target on shares of Danaher in a research report on Tuesday, September 26th. Cowen reissued a “buy” rating and issued a $90.00 price target on shares of Danaher in a research report on Wednesday, October 4th. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a research report on Thursday, October 5th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $95.00 price target (up previously from $86.00) on shares of Danaher in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $93.31.
In other Danaher news, CFO Daniel L. Comas sold 88,184 shares of the business’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the completion of the sale, the chief financial officer now directly owns 227,816 shares of the company’s stock, valued at approximately $20,735,812.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Robert S. Lutz sold 11,189 shares of the business’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $91.66, for a total value of $1,025,583.74. Following the sale, the chief accounting officer now directly owns 18,314 shares of the company’s stock, valued at $1,678,661.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2017/12/09/segall-bryant-hamill-llc-boosts-position-in-danaher-corporation-dhr.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.